Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Centessa Pharmaceuticals plc

35 indications, side-by-side phase, drug & LoA

$39.72

-0.05 (-0.13%)

D 36Pipeline Score Overvalued Pharma · Commercial
Market Cap
6.15 B
EPS
-1.77
P/E Ratio
-
Value Trade
33.49 M
SEC Financials
Q1 2026

  • Dilution Risk

    40%

  • Revenue

    -

  • R&D Expenses

    59.89 M

  • Operating CF

    -72.22 M

  • Total Assets

    641.76 M

  • Total Liabilities

    154.41 M

  • Equity

    487.35 M

  • D/E Ratio

    12,345

0.38 %
Week
0.56 %
1 Month
59.32 %
3 Month
43.35 %
6 Month
96.3 %
5 Year
96.3 %
All Time
Cash Data
Caution

  • Cash Position

    276.59 M

  • Monthly Burn

    24.07 M

  • Runway

    10.3 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 5, 2026
Overview
Volume
1.32 M
52 Week Range
10.95 - 40.26
% held by Insiders
29.35 %
% held by Institutions
70.86 %
Enterprise Value
5.99 B
Total Shares
154.73 M
Short %
2.35 %
Float Shares
109.31 M
Company Description
HQ: 3RD FLOOR, ALTRINCHAM, CHESHIR...
Employees:129
https://www.centessa.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D36
Pipeline Score
$515M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.3x
rNPV / MCap
Top 50%
Small Cap
(rank 453 of 905)
Percentile Rank
Centessa Pharmaceuticals plc faces pipeline headwinds (36/100), with $1.1B risk-adjusted pipeline value, led by SerpinPC in Hemophilia a (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
SerpinPC
Small molecule		Hemophilia aPhase 1NCT0407349846% $787M COMPLETED 39 - -Sep 26, 2024 -Feb 6, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ORX750
narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia
Phase 2a
2025-08-12
ORX750
narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia
Phase 2a
2025-08-12
ORX750
narcolepsy type 1,narcolepsy type 2,idiopathic hypersomnia
Phase 2a
2025-08-12
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CNTA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CNTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CNTA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CNTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2027-01-15 0.00 0 - - - - - -
2027-01-15 0.00 0 - - - - - -
2027-01-15 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Centessa Pharmaceuticals plc (CNTA) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CNTA ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Sleep Disorders #9 of 14 PHASE 2 ORX750
LLY AMGN INSP
$3.95B 0.91 FOLLOWER